Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Fox

Showing results (61-70 of 127) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|December 15, 2018
Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysisNicolás Martínez-Calle, Sarah Hartley, Matthew Ahearne, et al.
British Journal of Haematology|August 9, 2021
Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United KingdomFurqaan A Kaji, Nicolas Martinez-Calle, Mark J Bishton, et al.
Blood|July 31, 2010
A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapyChristopher P Fox, Tracey A Haigh, Graham S Taylor, et al.
Leukemia & Lymphoma|February 9, 2023
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphomaHoa Van Le, Kim Van Naarden Braun, Grzegorz S Nowakowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2026
Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell LymphomaNeha Mehta-Shah, Pier Luigi Zinzani, Eric D Jacobsen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 21, 2016
Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin LymphomaYasmin Reyal, Irfan Kayani, Adrian J C Bloor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2023
High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell LymphomaKatharine L Lewis, Lasse H Jakobsen, Diego Villa, et al.
JAMA Oncology|February 23, 2018
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical TrialsSusan M O'Brien, Samantha Jaglowski, John C Byrd, et al.
Hematological Oncology|August 17, 2019
Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysisAndreas M Schmitt, Amanda K Herbrand, Christopher P Fox, et al.
Lancet (London, England)|July 2, 2023
Predicting COVID-19 infection risk in people who are immunocompromised by antibody testingRatna Wijaya, Marina Johnson, Nicola Campbell, et al.
Pageof 13

Showing results (61-70 of 127) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|December 15, 2018
Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysisNicolás Martínez-Calle, Sarah Hartley, Matthew Ahearne, et al.
British Journal of Haematology|August 9, 2021
Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United KingdomFurqaan A Kaji, Nicolas Martinez-Calle, Mark J Bishton, et al.
Blood|July 31, 2010
A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapyChristopher P Fox, Tracey A Haigh, Graham S Taylor, et al.
Leukemia & Lymphoma|February 9, 2023
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphomaHoa Van Le, Kim Van Naarden Braun, Grzegorz S Nowakowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2026
Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell LymphomaNeha Mehta-Shah, Pier Luigi Zinzani, Eric D Jacobsen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 21, 2016
Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin LymphomaYasmin Reyal, Irfan Kayani, Adrian J C Bloor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2023
High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell LymphomaKatharine L Lewis, Lasse H Jakobsen, Diego Villa, et al.
JAMA Oncology|February 23, 2018
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical TrialsSusan M O'Brien, Samantha Jaglowski, John C Byrd, et al.
Hematological Oncology|August 17, 2019
Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysisAndreas M Schmitt, Amanda K Herbrand, Christopher P Fox, et al.
Lancet (London, England)|July 2, 2023
Predicting COVID-19 infection risk in people who are immunocompromised by antibody testingRatna Wijaya, Marina Johnson, Nicola Campbell, et al.
Pageof 13